Canada approved a generic semaglutide product as a Wegovy/Ozempic alternative, supplied by Dr. Reddy’s Laboratories and sold by prescription, making it the first G7 country to greenlight a semaglutide generic. The move also signals potential for additional generic entrants as the government considers eight more semaglutide alternatives. The decision arrives as Eli Lilly pushes oral GLP-1 competition with orforglipron and as semaglutide patents expired in India, where dozens of generics have already moved quickly to market. The approval raises the likelihood of price compression for GLP-1s in Canada. For biotech and pharma, generic approvals in high-revenue metabolic franchises can change commercial planning across dosing formats, including oral versions and next-generation molecules. It also increases emphasis on localized pricing strategies and payer negotiations. The development highlights a key access lever: where competition increases, affordability and utilization often shift, reshaping demand projections for branded producers.